2 Healthcare Stocks to Buy in a Bear Market

• Johnson & Johnson and Abbott Laboratories are diversified healthcare companies with charismatic prospects.

• Both person raised their dividends for implicit 50 consecutive years.

• 10 stocks we similar amended than Johnson & Johnson ›

It mightiness not look similar it, but the S&P 500 flirted with carnivore marketplace territory earlier this year. It has rebounded nicely since, but it's ever worthy considering which stocks would beryllium worthy buying if we participate a carnivore market. Turning to the healthcare assemblage -- which is astir arsenic antiaircraft arsenic they travel -- is simply a large idea.

Many healthcare companies execute well, oregon astatine slightest amended than most, done bully and atrocious times. With that arsenic a backdrop, let's see 2 fantabulous healthcare stocks to bargain successful a carnivore market: Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT).

Johnson & Johnson is simply a diversified healthcare leader. The company's concern spans innovative pharmaceuticals, wherever it develops products crossed a scope of therapeutic areas, including immunology, oncology, neuroscience, infectious diseases, and more. Then determination is Johnson & Johnson's medtech division, which besides spans respective areas. The institution generates accordant gross and profits. The concern isn't flashy, but it gets the occupation done.

The request for Johnson & Johnson's aesculapian products remains reasonably high, which enables the institution to grounds comparatively beardown results adjacent erstwhile the system is weak.

Further, Johnson & Johnson has the highest recognition standing available. While immoderate corporations look fiscal troubles and are incapable to fulfill their obligations, that's improbable to hap to this healthcare giant. Lastly, it is simply a fantastic income stock. Johnson & Johnson is simply a Dividend King, a institution that has maintained an progressive streak of astatine slightest 50 consecutive years of dividend increases. Johnson & Johnson is astatine 63. This provides adjacent much grounds that the institution tin execute good -- and rise its payouts -- done bully and atrocious times, making it a apical banal to bargain successful a carnivore market.

Abbott Laboratories checks galore of the aforesaid boxes arsenic Johnson & Johnson. It's a healthcare person with a concern spanning aesculapian devices, nutrition, diagnostics, and pharmaceuticals. The company's diversification enables it to get done challenging times. If 1 conception suffers, the others prime up the slack. The result: reliable (albeit not exceptional) gross and net growth.

Abbott besides has charismatic maturation prospects, with nary much appealing than its enactment successful diabetes care. Abbott's FreeStyle Libre, a franchise of continuous glucose monitoring devices, has been its biggest maturation operator for years and is expected to stay truthful for a while, considering the marketplace remains underpenetrated. Abbott is besides seeking caller avenues for growth. A caller acquisition volition let it to marque waves successful the crab diagnostic market.